Vaccinex, Inc. (Nasdaq: VCNX) is a biotechnology company focused on developing novel therapies for neurodegenerative diseases and cancer. The company's primary drug candidate, pepinemab, targets semaphorin 4D (SEMA4D), a protein implicated in neuroinflammation, which is a key factor in neurodegenerative conditions. Pepinemab is currently in clinical trials and has shown potential as a disease-modifying treatment. In addition to its applications in neurology, pepinemab is being investigated for its ability to improve responses in oncology when used in combination with checkpoint inhibitors. Vaccinex operates in the biopharmaceutical market, serving patients with unmet medical needs in neurology and oncology. The company generates revenue through partnerships, licensing agreements, and its proprietary drug discovery services, which include Antibody Discovery, Complex Membrane Antigens, Target Identification, and Protein Optimization. These services help other pharmaceutical companies accelerate their drug development processes from the research stage to clinical trials.

Keywords: neurodegenerative, oncology, semaphorin 4D, neuroinflammation, pepinemab, clinical trials, drug discovery, antibody discovery, protein optimization, checkpoint inhibitors.